Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 50 X 5 mg |
|
9283 |
Related information
Dosage
10 mg daily either as a single dose in the morning or in two divided doses of 5 mg, taken at breakfast and lunch.
Paediatric Use: The effects of selegiline in children have not been evaluated.
Indications
Treatment of Parkinson’s disease or symptomatic parkinsonism.
Contra-Indications
Selgin is contra-indicated in patients with known hypersensitivity (including severe dizziness or hypotension) to selegiline or any of the excipients.
Selgin is contra-indicated in patients receiving treatment with serotonin-agonists (e.g. sumatriptan, naratriptan, zolmitriptan and rizatriptan).
Selegiline is also contra-indicated for concomitant use with pethidine and other opioids.
Selegiline should not be used in patients who are being treated with antidepressant drugs, including MAO inhibitors, tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors (SNRI) (venlafaxine) and selective serotonin reuptake inhibitors (e.g citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline).
Selegiline should also not be used with other drugs which are also monoamine oxidase inhibitors, e.g. linezolid. Selegiline should not be used in combination with sympathomimetics.
Selegiline should not be used in patients with active duodenal or gastric ulcer.
Selegiline should not be used in patients with other extrapyramidal disorders not related to dopamine deficiency.
Selegiline in combination with levodopa is contra-indicated in severe cardiovascular disease, arterial hypertension, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma, prostatic adenoma with appearance of residual urine, tachycardia, arrhythmias, severe angina pectoris, psychoses, advanced dementia and thyrotoxicosis.
